Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients

Opinion
Video

Panelists discuss how referral types for multiple myeloma patients vary widely, including newly diagnosed cases, relapsed/refractory disease, and specific therapy considerations like bispecifics, with processes differing between in-state and out-of-state referrals due to logistical and insurance factors.

Video content above is prompted by the following:

  • What types of referrals do you usually do?
  • Is the process similar/different for in-state vs out-state?

  • Dr Saspu and Dr Shunyakov: How do social factors play into the referral process?
  • Dr Saspu and Dr Shunyakov: How do the AEs differ based on the class of bispecific? Which AEs are you seeing in practice?
  • How are they managed?
Recent Videos
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series
BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.
Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
Related Content